Please login to the form below

EvaluatePharma

This page shows the latest EvaluatePharma news and features for those working in and with pharma, biotech and healthcare.

By EvaluatePharma’s forecasts, the global rare disease market is set to grow by a low double digit percentage until 2026.

Biogen triumphs over Mylan’s Tecfidera patent challenge

For comparison, while Tecfidera is a billion-dollar product, EvaluatePharma has forecast sales of Vumerity to reach a modest $111m in 2024.
Roche builds case for SMA drug risdiplam as FDA verdict nears

EvaluatePharma has predicted that risdiplam could become an $800m-plus drug by 2024, and other analysts have said it could make upwards of $2.5bn at its peak.
Troubled Alkermes eyes November OK for new antipsychotic

EvaluatePharma has previously predicted that sales of ALKS 381 could reach $381m in 2024 if approved, which would be a sizeable addition to its current revenues, expected to reach a little
Novo Nordisk gets MACE prevention claim for Ozempic in US

EvaluatePharma has previously predicted that Ozempic could become a $2.2bn product by 2022, but other analysts think it could go even higher, perhaps reaching $3bn plus at its peak.
Lynparza cleared for first-line ovarian cancer use in China

EvaluatePharma has projected that the Lynparza will continue to grow to produce annual revenues of $2.2bn by 2024.

More from news
Approximately 3 fully matching, plus 68 partially matching documents found.

It started with a miss

The stakes are high and getting higher. A recent report from EvaluatePharma forecasts that pharma is on the brink of a second patent cliff, with worldwide drug sales of over $198bn
Drug launches to watch in 2019

EvaluatePharma has predicted it could become a nearly $2.5bn product by 2024, providing it can also pick up approvals in AML and other indications like multiple myeloma.
AstraZeneca’s oncology renaissance

EvaluatePharma forecasts that Lynparza (now co-marketed with Merck &Co) will hit annual revenues of $2.2bn by 2024, with Imfinzi expected to reach $3.65bn and Tagrisso leading the way
The handover: Pfizer reshapes itself for a new era

The company is currently the pharma industry’s biggest player by revenue (earning $45.4bn in 2017), but analysts EvaluatePharma expect Novartis to overtake it by 2024.
Deal Watch May 2016

A recent analysis through 2015 made by EvaluatePharma shows that six of the top ten pharma companies will derive less than 20% of drug sales from products that were developed from

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Early Access Program - Regulatory Affairs (EAP-RA): Highly competitive salary

Associate Director - Global Healthcare Consulting: £100,000 - £115,000 yearly

Add my company

We are the world's most celebrated and awarded Medical Communications agencies. We are 800 experts obsessed with combining science, creativity...

The speed of science and the pace of comms: Pharma red tape slows comms but there is a solution, Paul Hutchings, founder of fox&cat, writes....
Improving cardiovascular disease care and awareness: Scott Curley talks to PME about the risks of CVD and the importance of getting the right treatment at the right time...
Virtual Patient Engagement Program: A Customer Story: Our client wanted to better understand the needs, preferences, and treatment gaps among adult patients with a rare genetic disease......

Email:
Password: